G-CSF ameliorated neutropenia and allowed significant further escalation of losoxantrone dose to 125 mg m−2, at which three out of five patients developed febrile neutropenia which defined this dose as the new MTD. Here, CSF3 is linked to Decreased total neutrophil count.